Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease
Douglas B. Kuhns(Leidos (United States)), John I. Gallin(National Institute of Allergy and Infectious Diseases), Harry L. Malech(University of Maryland, Baltimore), Kol A. Zarember(National Institutes of Health), Jordan J. Feld(University Health Network), Debra A. Long Priel(Science Applications International Corporation (United States)), Steven M. Holland(National Institute of Allergy and Infectious Diseases), Kristen Pike(Science Applications International Corporation (United States)), Theo Heller(National Institutes of Health), Beatriz E. Marciano(National Institutes of Health), Suk See De Ravin(National Institutes of Health), Gülbû Uzel(National Institutes of Health), Benjamin P. Soule(Sun Pharma (United States)), W. Gregory Alvord(Data Management Services (United States))
Cited by 560
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
|Medicine|2000|1.7k
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|New England Journal of Medicine|2014|907